Mossner, M., Jann, J., Nowak, D., Pressler, J., Obländer, J., Fey, S., . . . Nolte, F. (2016). Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: Results from a prospective multicenter study of the german MDS study group (GMDS). Leukemia, 30(9), . https://doi.org/10.1038/leu.2016.111
Chicago-Zitierstil (17. Ausg.)Mossner, Maximilian, et al. "Prevalence, Clonal Dynamics and Clinical Impact of TP53 Mutations in Patients with Myelodysplastic Syndrome with Isolated Deletion (5q) Treated with Lenalidomide: Results from a Prospective Multicenter Study of the German MDS Study Group (GMDS)." Leukemia 30, no. 9 (2016). https://doi.org/10.1038/leu.2016.111.
MLA-Zitierstil (9. Ausg.)Mossner, Maximilian, et al. "Prevalence, Clonal Dynamics and Clinical Impact of TP53 Mutations in Patients with Myelodysplastic Syndrome with Isolated Deletion (5q) Treated with Lenalidomide: Results from a Prospective Multicenter Study of the German MDS Study Group (GMDS)." Leukemia, vol. 30, no. 9, 2016, https://doi.org/10.1038/leu.2016.111.